StemCell Therapy

Data from the Ohio Department of Health states that in 2016, nearly 1 million (11.1 percent) Ohio adults had been diagnosed with diabetes. In addition, nearly 800,000 adults in Ohio had been diagnosed with prediabetes, and it is estimated that more than 1 million Ohio adults have prediabetes but have not been diagnosed, increasing their risk of progressing to type 2 diabetes later in life.Becausethe longer someone has diabetes, the higher risk they face for developing vision issues, and health disparities continue to affect minority populations, the Ohio Affiliate of Prevent Blindness has declared November as Diabetes-related Eye Disease Month. Educational resources include downloadable factsheets, training modules, social media graphics and more. Materials are available in English and Spanish.

Diabetes-related eye disease refers to eye problems that people with diabetes may face as a complication of the disease.Diabetes-related retinopathy(DR) is a disease that damages the blood vessels of the eye, causing them to leak and bleed into the retina.

Individuals may not experience symptoms in the early stages of DR, which is why it is important for individuals with diabetes to have an eye exam annually, or as directed by their doctor.

If diabetes-related retinopathy is left untreated, fluid can leak into the center of the macula, called the fovea, the part of the eye where sharp, straight-ahead vision occurs. The fluid makes the macula swell, blurring vision. This condition is calleddiabetes-related macular edema.It can occur at any stage of diabetic retinopathy, although it is more likely to occur as the disease progresses.

Other eye conditions common among people living with diabetes include:

Cataract, a clouding of the lens in the eye, which can cause vision to become blurry and colors to become dull. Aside from aging, diabetes is the most common risk factor for cataract.

Glaucoma occurs with damage to the optic nerve and possible loss of side vision, usually caused by an increase in fluid pressure inside the eye.

According to theNational Institute of Diabetes and Digestive and Kidney Diseases,finding and treating diabetic retinopathy early can reduce the risk of blindness by 95 percent."Nearly 300,000 Ohioans have diabetes-related eye disease," said Sherry Williams, President & CEO of the Ohio Affiliate of Prevent Blindness. Education, advocacy and access to care are key to helping to prevent vision loss from diabetes.By working together to increase early detection, consistent monitoring, and treatment, we can help to avoid significant vision loss, including blindness, across Ohio and the country.The Center for Vision and Population Health at Prevent Blindness offers the Seeing the Way to Better Health: Diabetes and Vision Healthissue brief.The goal of the brief is to encourage diabetes health programs to integrate vision into their outreach and programs. It includes stories from peer programs, resources and infographics for program use. The brief was developed in partnership with theNational Association of Chronic Disease Directors.TheDiabetes & the Eyes Educational Toolkitfrom Prevent Blindness offers free educational materials on diabetes and the impact of diabetes on eye health in English and Spanish. These educational resources are intended for healthcare professionals, community health educators, diabetes educators and anyone in a caregiving or diabetes education role. The development of the toolkit was made possible by funding from the Allergan Foundation.

For those who have vision loss from diabetes, Prevent Blindness offers the freeLiving Well with Low Visiononline resource. The site includes the Low Vision: A Self-Help Guide, the Caring for the Visually Impaired guide, and a variety of self-help tools and resource links at:http://lowvision.preventblindness.org/.For more information on diabetes-related eye disease, please visithttps://preventblindness.org/diabetes-and-your-eyes/or call Prevent Blindness at 800-301-2020. For a free listing of organizations and services that provide financial assistance for vision care in English or Spanish, please visithttps://preventblindness.org/vision-care-financial-assistance-information/.

About Prevent Blindness, Ohio Affiliate:

Founded in 1908, Prevent Blindness is the nation's leading volunteer eye health and safety organization dedicated to fighting blindness and saving sight. The Ohio Affiliate of Prevent Blindness serves all 88 Ohio counties, providing direct services to more than 1,000,000 Ohioans annually and educating millions of consumers about what they can do to protect and preserve their precious gift of sight. For more information or to contribute, call 800-301-2020.Visit Prevent Blindness on the web atpbohio.org, Facebook atfacebook.com/pbohio/ or Twitter attwitter.com/PB_Ohio.

Read the rest here:
Prevent Blindness declares November as Diabetes-Related Eye Disease Month to educate on leading cause of new cases of blindness in adults - The...

Jerome Jackson, 30, is a blind man who is fearful that his five-year-old daughter may also go blind because of a history of blindness in his family. Jackson lost his sight suddenly in 2001.

But before him, his grandmother and uncle lost their sight before doing surgery and repairing their vision.

His father and grand-uncle also went blind and haven't been able to see again. This is a 'family trend' he wants nowhere near his daughter, who recently had to get glasses.

"My grandmother got blind in 1988, but she got her sight back after three years. My uncle got blind and he got his sight back, too, after he did surgery in England. My grand-uncle was also blind, but he passed off. So, it's just me and my father leave now," Jackson told THE WEEKEND STAR.

The Woodford Park, Kingston resident says the thought that his daughter could have the same experience is frightening.

"I am totally blind and recently I took my daughter to the eye doctor. She's supposed to get a better (pair of) glasses to improve her sight, and it's about $50,000 for the glasses. The doctor said her eyes are not that bad, but the glasses will help her more. And the left eye is better than the right eye, so they have to triple the lens for the right eye. So, that's why I am trying to get the glasses for her, but it's challenging for me," he said. Jackson went blind when he was just 11 years old.

"I thought my eyes were bleeding. Everything was red. A teacher of mine passed off and my father and I went to her house. On our way back, I lost my sight. I don't know what happened. I don't know what's the cause of it all now," he recalled.

He was then admitted to Kingston Public Hospital for five months, where he learnt that there was a scar and infection behind his retina.

He has no idea what his daughter looks like. "I haven't seen her. That pains me every day," he related. "My dad got blind when he was 20. He has three of us and him don't know how none of us look.

Since February, Jackson has been facing challenging times after he lost his source of income in February. The COVID-19 pandemic came one month later and made life harder.

"I was working as a massage therapist with the empowerment programme through the National Youth Service, but there's nothing there for me anymore. I usually get some assistance from a charity, but I still have problems paying my rent sometimes," he said.

Jackson began studying at The University of the West Indies in 2014 and was reading for a degree in entertainment management and culture. However, he has to sit out a year due to financial issues.

Dr Peter Swaby, ophthalmologist, told THE WEEKEND STAR that "We need to know the cause of blindness for at least two of the relatives before we can ascertain whether it is genetic."

Jackson said his grandmother had cataracts, which were removed to repair her vision. But Swaby noted "If it's a hereditary link we're looking at, that information from the grandmother wouldn't be enough."

If anyone can assist Jerome Jackson, you can contact him at 876-815-6994 or 876-919-5201.

See the original post:
History of blindness in family - Father worried daughter may also lose her sight - Jamaica Star Online

Better Cotton uptake accounts for 6% of global cotton production

The findings are set out in the'BCI Task Force on Forced Labour and Decent Work: Final report and recommendations,' which notes:"While BCI explicitly cites the promotion of decent work as one of its core objectives, the level of attention and investment thus far has been insufficient.

"This is clear across many areas of BCI, including new country start-up evaluations, implementing partner selection, onboarding and project development, and findings from second and third-party assessments. The Task Force believes that this has resulted in organisational blindness to forced labour and likely other key decent work issues."

BCI trains farmers on more sustainable cotton production, with the BCSS covering all three pillars of sustainability social, environmental and economic and addressing the many challenges of cotton production. According to its last annual report, Better Cotton uptake accounts for 6% of global cotton production, and retailers and brands sourced more than1.5m metric tonnes of Better Cotton by the end of 2019 a 40% jump on the previous year.

The group appointed theindependent task forcein Aprilto review the current BCI systemand make suggestions to improve its effectivenessin identifying, preventing, mitigating and remediating forced labour risks.

Report authors say the initiative"now has an opportunity with the right level of commitment and resourcing to renew its focus on the more than 1.5 million workersat the foundation of the Better Cotton system, to give these workers a stronger voice, and to pioneer innovative, worker-focused approaches to promote decent work in cotton fields.

"Strengthening decent work capabilities and systems will also provide greater assurance to brands, retailers, and other stakeholders that farmers growing Better Cotton are following BCI's stated principles on forced labour and decent work."

The findings come a week afterBCI calledan immediate halt toall field-level activities in the Xinjiang Uyghur Autonomous Region (XUAR) of China, where ongoing allegations of forced labour and other human rights abuses "have contributed to an increasingly untenable operating environment." Earlier in the yearit suspended itslicensing and assurance activities in the XUAR, meaning there is now no new licensed Better Cotton coming from the region.

The task force also says BCI must acknowledge it cannot operate in regions where there is credible evidence of state-imposed forced labour.

The nine-point roadmap set out to help address the gaps and shortfalls in its decent work capability is grounded in international human rights standards, understanding inequalities, and addressing discriminatory practices.

In a statement following publication of the report, BCI says it recognises that strengthening its decent work programme will be a multi-year process and will require additional resources and funding.

"In the short-term, we will focus on strengthening our forced labour capabilities through capacity building for staff, implementing partners and third-party verifiers, enhancing our due diligence for selecting and retaining implementing partners, and revising our assurance processes to better identify and mitigate forced labour risks.

"In 2021, BCI is also exploring opportunities to pilot a more comprehensive set of decent work activities, including a detailed forced labour risk assessment and civil society engagement tactics, in one or two high priority regions."

Click here to read the Task Force's report in full.

Read the original:
Better Cotton accused of "blindness" to forced labour - just-style.com

According to the National Eye Institute, glaucoma is the second leading cause of blindness in developed countries. That is the reason for the prevention of this disease. Glaucoma can be developed by anyone, however, it is more common in people over age 45 or 60, and people with a family history of glaucoma. Generally, children can get a rare form of glaucoma early.

Glaucoma is

Lets begin with what is glaucoma. As we mentioned earlier, glaucoma is one of the leading causes of blindness for people. It can occur at any age, but it is more common in older people. It is a group of eye conditions that damage the optic nerve, which is an important part of good vision. The damage that causes glaucoma can be by abnormally high pressure in the eye.

Unfortunately, some forms of glaucoma have no warning signs, due to the gradual effect we dont notice a change in the vision until it is in an advanced stage. Also, the vision loss by glaucoma cannot be recovered. Therefore, it is important to consult a specialist commonly, if the glaucoma is recognized early, it is easier to prevent vision loss.

Depending on the stage and type of glaucoma it will show symptoms. Those include:

4 things that you must know about glaucoma

Like many diseases, glaucoma has things that must be known by the patients, this way will be easier to prevent and accept the fact that we have to consult a specialist such as an ophthalmologist commonly.

It is important to consult a specialist either when feeling discomfort and thinking that there may be a relationship with glaucoma, or just to keep your vision healthy.

With the collaboration of Dr. Mercedes Silva Orellana, an ophthalmologist graduated from the National University Mayor of San Marcos, in Per. Her specialties are Anterior Segment Surgery, Glaucoma Treatment, and Glaucoma Surgery, also offering treatment to patients suffering from closed-angle glaucoma, among others.

References:

comments

Go here to see the original:
This is what you need to know about glaucoma - The Yucatan Times

Every afternoon for three hours on SiriusXM radio, The Michelangelo Signorile Show has offered a lifeline of sanity and smart political discourse in these grueling and maddening times. Signorile has been fighting the good and progressive fight for decades, starting with his seminal writing on Queer America and gay activism (at one point serving as the head of ACT UPs media arm). Hes also developed his own online newsletter, The Signorile Report, where he covers the latest political horrors with thoughtful analysis.

INTERVIEW: Where are you and how long have you been isolating?

MICHELANGELO SIGNORILE: In Manhattan, since March 13.

INTERVIEW: What has this pandemic confirmed or altered about your view of society?

SIGNORILE: That things can move very swiftly, and everything can turn on a dime.

INTERVIEW: What is the worst-case scenario for the future?

SIGNORILE: We see more spikes, and no effective vaccine for a long timejust a few less-than-effective ones. I also worry about another virus coming out of nowhere.

INTERVIEW: What good can come out of this lockdown? Are there any reasons to hope?

SIGNORILE: For those lucky enough to keep their jobs and work at home, its been a time of creating better habits, seeing that we can all get on with less. Weve been through worse certainly as a gay man, Ive been through the HIV epidemic much of my adult lifeand many have come together to fight tyranny and negligence.

INTERVIEW: What has been your daily routine during this time?

SIGNORILE: Up early, scouring news, writing a bit, preparing for my radio show on weekdays. Exercise or a run. Shower, then three hours on the radio. Make dinner with my husband, maybe we watch some TV.

INTERVIEW: Describe the current state of your hair?

SIGNORILE: Im back to my barber once a week (in masks) to get a close buzz of whats left of my hair! But it was crazy there for a while.

INTERVIEW: On a scale of 1 to 10, what is your level of panic about the current state of the world?

SIGNORILE: Seven.

INTERVIEW: Do you think there is hope for true racial equality in the United States? What do you think is the first step in that goal?

SIGNORILE: Yes, there is always hope. It rises out of activism. But the first step is people realizing that the fight never ends, and that the wins ebb and flow. Too many people jump in, think they change laws, think its over. Its never over. People can change, they can be educatedand so can the government. It takes persistence, challenging all the time, and never thinking its done.

INTERVIEW: Do you think protests are effective tools for changing the system? How does it make a difference in the long term?

SIGNORILE: Protest is a voice. It screams for justice and is so important. It shuts down the daily routine and says, Listen up! It is also personally satisfying for those protesting, and necessary for their minds and bodies. Its empowering and it unites people. But it needs to be followed up by political organizing.

INTERVIEW: How do you personally channel your anger? Do you find anger to be a useful emotion?

SIGNORILE: Anger is vital. It gets you moving. I try to channel it by targeting those who need to be exposed or criticized or challenged, either in my writing or on the air. But sometimes my anger about one thinga Supreme Court nominationmight be channeled toward something or someone else, like seeing someone without a mask on the subway and telling them to put a damned mask on.

INTERVIEW: Which young leaders of the moment inspire you?

SIGNORILE: Just to name a few: Charlotte Clymer. DeRay McKesson. David Hogg. Gabe Ortz. Chase Strangio. Greta Thunberg. Indya Moore. Jared Holt. Juan Escalante. AOC. Alex Morse. Megan Rapinoe. So many more.

INTERVIEW: Whats the next step after protests in the streets? Where does the righteous rage go?

SIGNORILE: To more, and different, protests. Protests do not have to be large or in the streets. Targeted, sustained protest by small groupsof a particular senator, say, or some other government officialis just as effective. And being creative is so important in this media environment, because the goal is always about getting the message out. So you have to think of new ways to get attention. Secondly, it has to be a message that translates into policy change. Once you have peoples attention, people who are in power, and they really want to make a change, you have to have a concrete plan of action for them to work off of.

INTERVIEW: What thinker have you taken comfort in of late and why?

SIGNORILE: Laurie Garrett. She wrote the book The Coming Plague almost 25 years ago, and its been revelatory.

INTERVIEW: Where did we go wrong? Like, what was the exact moment?

SIGNORILE: Thinking wed arrived, thinking the fight for civil rightsfor so many groupswas over. This was during the Obama years. A complacencyI called it victory blindness in my last book.

INTERVIEW: Which (admittedly totally unqualified) celebrity would you trust with the planets future?

SIGNORILE: Jane Fonda, of course.

INTERVIEW: Whats one skill we should all learn while in quarantine?

SIGNORILE: Learning another language. Though I admit I havent done it.

INTERVIEW: What prevents you from giving up hope in the human race?

SIGNORILE: That people are alive, that they must survive, and that they will fight.

INTERVIEW: What is the most pressing issue facing the nation and the world that needs to be addressed in the next four years?

SIGNORILE: The planet is burning. We have to do what we can to stop it.

INTERVIEW: Who should be the next president of the United States?

SIGNORILE: Joe Biden, fingers crossed.

See the article here:
Michelangelo Signorile on the Perils of Complacency and Victory Blindness - Interview

A new therapy being developed to help restore vision to people who are blind could be used within years.

The treatment involves a "relatively simple" injection into the eye and is a "relatively straightforward surgery".

That's according to John Flannery, a Professor of Neurobiology in the Department of Molecular and Cell Biology at the University of Berkeley and a member of the Medical and Scientific Advisory Board for Fighting Blindness Ireland.

He told Futureproof with Johnathan McCrea how blindness develops in some people and how his research will attempt to remove the disease from patients.

His startup company has recently been bought by Novartis and they will partner to develop the treatment.

Professor Flannery said "the hope is for some patients, they'll get a significant increase in their vision".

He added that "manufacturing enough of the treatment is not doing to be that difficult".

In explaining how blindness develops in some people, Professor Flannery said "almost all the inherited blindnesses occur over time".

He said: "The gene defect you have when you're born, and depending on what you inherit, it can manifest as a small child or sometimes not until you're a teenager and some conditions, likemacular degeneration, not until you're 50 or 60."

Professor Flannery said technology is been tested to get the eye to see something when there's no biological retina, but that its success is a long time away.

He said: "There have been some attempts to connect a video camera to the patient's brain in patients that are completely blind.

"That's been incredibly challenging because we know quite a bit about how the retina works but we don't know much about it encodes the signal.

"That will be quite a bit off until we have an electronic prosthetic.

"Nobody, in my knowledge, has been able to interpret the signals coming out of the eye and understanding what the picture is."

Professor Flannery said his research on how to develop therapies for blind patients starts out on testing with animals such as mice.

He said that the current treatments available to patients are for those who have recessive conditions, meaning they got the gene from both of their parents, which continues much of his work.

Professor Flannery explained how the therapy aimed to cure blindness would work.

He said: "The progress in the field has been to use the shell of the virus, the outside coat of the virus.

"We use a very different virus for the eye that's never been shown to cause disease, we put in a copy of the gene that the patient has a defect in.

"We use the virus shell to carry the DNA and protect it and that virus will carry the DNA into the retinal shells and that's a one time only repair."

He said that the virus contains a "zip-code" which controls which cells have the therapeutic gene.

Professor Flannery added: "It's a question of scale, a normal human has 150 million photoreceptors, which are the ones that are affected in these conditions.

"You can inject with a very small volume many hundreds of million virus particles."

Professor Flannery said that an experiment showed that blind mice were able to move around and explore as much as other mice.

He said: "In a couple of the therapies that are currently in the clinic, the patients have to be treated as quickly as possible because their photoreceptor cells are dying and if you get to the stage where theirphotoreceptors have died, the gene in the cell is gone.

"The therapy that we're trying to develop, which is called optogenetics, is for patients at the very late stages of blindness.

"What we're doing is capitalising on the knowledge that the photoreceptors talk to other cells in the retina that aren't light-sensitive

"Our gene therapy is designed to add light sensitively to the third cell in this chain between the damaged photo and the brain.

"Since it's in the middle, if you can make that cell light-sensitive, that's a new opportunity for restoring vision in the blind.

Professor Flannery said this treatment is "particularly appealing because you could treat someone at any age or any stage".

He said: "Because unlike the other therapies where you have to identify the exact genetic defect in the patient and put that exact gene back, this is putting a light-sensitive function in a different cell.

"It doesn't require you to know what the defect is in the patients."

Professor Flannery said they would begin to start testing the therapy in small groups of patients shortly after successful trials in dogs.

You can listen back to the full interview here:

'Relatively simple' therapy could help cure blindness

00:00:00 / 00:00:00

The rest is here:
'Relatively simple' therapy could help cure blindness - Newstalk

This article was originally published here

Psychon Bull Rev. 2020 Nov 2. doi: 10.3758/s13423-020-01826-4. Online ahead of print.

ABSTRACT

Retrospectively obvious events are frequently missed when attention is engaged in another task-a phenomenon known as inattentional blindness. Although the task characteristics that predict inattentional blindness rates are relatively well understood, the observer characteristics that predict inattentional blindness rates are largely unknown. Previously, expert radiologists showed a surprising rate of inattentional blindness to a gorilla photoshopped into a CT scan during lung-cancer screening. However, inattentional blindness rates were higher for a group of nave observers performing the same task, suggesting that perceptual expertise may provide protection against inattentional blindness. Here, we tested whether expertise in radiology predicts inattentional blindness rates for unexpected abnormalities that were clinically relevant. Fifty radiologists evaluated CT scans for lung cancer. The final case contained a large (9.1 cm) breast mass and lymphadenopathy. When their attention was focused on searching for lung nodules, 66% of radiologists did not detect breast cancer and 30% did not detect lymphadenopathy. In contrast, only 3% and 10% of radiologists (N = 30), respectively, missed these abnormalities in a follow-up study when searching for a broader range of abnormalities. Neither experience, primary task performance, nor search behavior predicted which radiologists missed the unexpected abnormalities. These findings suggest perceptual expertise does not protect against inattentional blindness, even for unexpected stimuli that are within the domain of expertise.

PMID:33140228 | DOI:10.3758/s13423-020-01826-4

Originally posted here:
The invisible breast cancer: Experience does not protect against inattentional blindness to clinically relevant findings in radiology - DocWire News

A transit app arrives for KCs visually impaired // Photo courtesy of Alphapointe.org

The Kansas City Area Transportation Authority (KCATA), Alphapointe, and Sensible Innovationhave partnered to develop an app for the blind and visually impaired to use transit more safely and accurately. It marks the first application of its kind to be applied to an entire transit corridor in the United States.

The mobile app, RideKC Navigator, is a custom platform to help individuals with vision impairment or blindness navigate select transit stops. The free RideKC Navigator app can be downloaded on both iOS and Android devices. Users will receive location-specific audio instructions to help navigate 51 bus stops, East Village Transit Center, 75th Street Transit Center, and 31 intersections in Kansas City, MO.

The app was created as part of KCATAs Prospect MAX Bus Rapid Transit (BRT) 10-mile corridor project. The corridor runs from the 75th and Prospect Transit Center at Alphapointe, north on Prospect to 12th Street, and west along 12th Street into downtown Kansas City.

KCATA President and CEO Robbie Makinen credited Alphapointe for playing a critical role in testing and developing RideKC Navigator. Our visually impaired experts at Alphapointe navigate the real world on a daily basis. Their help in orientation and mobility instructions, testing and tutorials was invaluable, Makinen says.

Reinhard Mabry, President and CEO of Alphapointe, says the business is one of the largest employer of blind and visually impaired people in Missouri, as well as nationwide. This app will open up the community to people who are blind, Mabry says. It will prepare people who have visual impairment to navigate spaces and areas of the community that they may not have been comfortable with previously because they didnt know enough about their surroundings.

Alphapointe adaptive technology instructor Jim Fettgather is visually impaired and assisted with the development and testing of RideKC Navigator. To have this app in Kansas City is an incredible, innovative experience, says Fettgather.

For more information, watch this video that provides greater insight on the benefits of RideKC Navigator.

View original post here:
Locals partner to create first transit app for the visually impaired in KC - Kansas City Pitch

Inherited retinal diseases marketis expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to an annual growth rate of 4.40% in the above-mentioned forecast period.

Based on type, inherited retinal diseases market is segmented into leber congenital amaurosis (LCA), retinitis pigmentosa, choroideremia, stargardts disease, and achromatopsia.

Inherited retinal diseases market has also been segmented based on treatment type such as gene therapy treatment, and symptomatic treatment.On the basis of distribution channel, the inherited retinal diseases market is segmented into hospital pharmacies, and retail pharmacies.

Inquiry For Customize Report With Discount at :https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-inherited-retinal-diseases-market

Global Inherited Retinal Diseases Market Drivers:

he growing awareness amongst the physicians and patients regarding the benefits associated with the usage of inherited retinal diseases has been directly impacting the growth of inherited retinal diseases market.

The swelling prevalence of the acquired retinal disorders is foreseen to push the growth of inherited retinal diseases treatment market. Expanding knowledge and treatment-seeking flow is anticipated to feed the germination of the inherited retinal diseases therapy business. Emphasizing knowledge of the inherited retinal disease surgery options and analysis of the condition is moreover awaited to magnify the growth of the inherited retinal disease surgery market.

The production businesses in the inherited retinal diseases market is moreover concentrating on the gene mutation-specific way for developing innovative outputs which is anticipated to accelerate the growth of inherited retinal diseases market. Numerous companies are contracting in collaborations, businesses to perform clinical experiments to promote acquired retinal disorder medication alternatives more efficiently. These certain mentioned factors are expected to drive the market growth in the forecasted period of 2020 to 2027.

For more analysis on theinherited retinal diseasesmarket, request for a briefing with our analystshttps://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-inherited-retinal-diseases-market

Table of Contents:

1 Introduction

2 Research Methodologies

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Industry Trends

7 Compliance in Inherited Retinal Diseases Market

8 Inherited Retinal Diseases Market, By Service

9 Inherited Retinal Diseases Market, By Deployment Type

10 Inherited Retinal Diseases Market, By Organization Size

11 Inherited Retinal Diseases Market Analyses, By Vertical

12 Geographic Analyses

13 Competitive Landscapes

14 Detailed Company Profiles

15 Related Reports

To know more about the study,https://www.databridgemarketresearch.com/reports/global-inherited-retinal-diseases-market

About Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact:Data Bridge Market ResearchUS: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475Email:Corporatesales@databridgemarketresearch.com

See more here:
Global Inherited Retinal Diseases Market Is Growing In Huge Demand In 2020 ||Invitae Corporation., The Choroideremia Research Foundation Inc, American...

Dennis Kigen has a flock of 148 birds of mixed ages in his farm in Kiserian. He got the stock to start his farm from this home village early last year. Last week, he started observing dark pimples on the unfeathered parts of the body of the eight-week-oldchicks and yellow lesions in the mouth and blindness among the growers which are about 4 months old. He has never had his flock vaccinated. He was worried about this condition and called me.

I visited the farm last weekend. From the vaccination history and the presenting clinical signs it was clear that his flock had developed Fowl pox.

Lets discuss this peculiar disease.

Fowl pox is a disease that occurs worldwide. All species of birds are affected. All ages are affected as well.

It is caused by Avian pox viruses which are single, linear double stranded DNA viruses. The virus comes from the same family as the viruses that cause sheep, goat and cow pox.

The effects of the disease;

Its incubation is from 4-10 days. There are two forms of the disease- cutaneous dry and diphtheritic or wet. Both may present in the same flock. The dry form is manifest as pimples or scabs on the skin (mainly on unfeathered parts of the body). The diphtheritic form shows cankers or yellow lesions in the mouth, esophagus or trachea. Other symptoms include blindness, feed refusal, lowered egg production, facial swelling.

Subscribe to Our Newsletter

Subscribe to our newsletter and stay updated on the latest developments andspecialoffers!

How does this disease spread?

The disease is transmitted through mosquito bites and mechanical transmission of virus to injured skin or eye are common routes of viral spread. Wild birds are a reservoir for the viruses.

What are the presenting clinical signs?

Incubation period is from 4-10 days. They are two forms of the disease; the cutaneous or dry and the diphtheritic or wet. Both may be present in the same flock or animals.

The dry form shows as a pimple or scab on skin mainly comb, wattles, eyelids and other unfeathered portions of the body.

The wet-mucous form shows diphtheritic, cankers or yellow lesions in mouth, esophagus or trachea. Eye involvement (blindness), off feed, lower egg production, facial swelling and an increase in culls can be seen.

The disease has a high morbidity rate and a low mortality rate. This means that it spreads to many birds in the farm but very few die if any.

What are the postmortem lesions?

Cankers or false membranes in mouth (wet) are seen as slightly elevated white opaque nodules. Nodules increase in size and coalesce to yellow, cheesy, and necrotic membranes.

Grey or black papular eruptions on unfeathered portions of skin (dry). Head, face, and feet are most commonly affected, but may spread to feathered portions of the body.

How to treat & control Fowl pox?

Being a viral disease, it has no specific treatment.

However, at the advice of the attending Vet, antibiotics may be administered to counter secondary infections. The withdrawal period for eggs and meat must be observed. Administration of multivitamins help to restore immunity and hasten recovery.

What are the preventive measures?

Vaccinate chicks when they are 8 10 weeks by wing web puncture method. The vaccination regime against all the other poultry diseases as well as deworming should be strictly adhered to.

After administration, vaccines take at least 2 weeks to take good protective effect. Do not use antibiotics and other drugs such as dewormers together with vaccines. They may interfere with the protective effects of the vaccine.

By adopting proper vaccination regimes, youll save your farm from losses accruing due to loss of production, Vet fees for treatment, culling and massive deaths.

Read the rest here:
How to prevent Fowl pox from affecting your flock of birds - The Standard

Market Report Summary

For Full Information -> Click Here

Read Full Press Release Below

According to a new market report published by Persistence Market Research Global Market Study on Ophthalmic Devices: Asia to Witness Highest Growth by 2020, the global ophthalmic devices market was valued at USD 29,171.5 million in 2014 and is expected to grow at a CAGR of 6.5% from 2014 to 2020, to reach an estimated value of USD 42,685.1 million in 2020.

Globally, the ophthalmic devices market is witnessing significant growth due to increasing prevalence of eye disorders, such as diabetic retinopathy and macular degeneration. In addition, growing global aging population, increasing government initiatives towards healthcare infrastructure in developing countries, and increasing incidence of lifestyle-associated diseases are also driving the growth of the market.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/3188

Some of the major players in the global ophthalmic devices market:

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/3188

However, lack of awareness among people about eye disorders, poor primary healthcare infrastructure, and lack of insurance in developing countries hamper growth of the global ophthalmic devices market. In addition, eye diseases in children are also increasing due to the general lack of awareness.

The global ophthalmic devices market is anticipated to grow from an estimated USD 29,171.5 million in 2014 to USD 42,685.1 million in 2020 at a CAGR of 6.5% during the forecast period.

Age-related eye diseases, such as glaucoma, cataract, diabetic retinopathy, and age-related macular degeneration, are the leading causes of visual impairment and blindness in North America. According to the American Academy of Ophthalmology, approximately 22 million Americans aged 40 and above were affected by cataract and 2.3 million Americans were affected by glaucoma in 2011.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/3188

In Europe, increasing prevalence of chronic eye diseases among the rising aging population is becoming a challenge for the European healthcare system. In France, the number of age-related macular degeneration cases was 0.3 million in 2000 and it is anticipated to increase by 0.5 million in 2020.

However, glaucoma, cataract, and diabetic retinopathy are the major causes of blindness in Asia. Cataract can be held responsible for 50% to 80% of all cases of blindness in Southeast Asia. The prevalence of age-related macular degeneration is also increasing in Asia due to increase in life expectancy and rising incidence of diabetes among the younger population. As per the Centre for Eye Research Australia, prevalence of diabetic retinopathy among people ranged between 17% and 22% in India and 43.1% in rural China in 2012.

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Ashish KoltePersistence Market ResearchAddress 305 Broadway, 7th FloorNew York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Website https://www.persistencemarketresearch.com

View post:
The Ophthalmic Devices Market To Revive The Growth Indices, Reach US$ 42.68 Bn - Eurowire

In a paper published today in the journal Cell, scientists describe unexpected, undesirable outcomes after editing genes in human embryos with CRISPR, a genomic editing system.

The study, the most detailed analysis to date of CRISPR in human embryos, shows that applying gene editing technologyto repair a blindness-causing gene early in the development of a human embryo often eliminates an entire chromosome or a large section of it.

"Our study shows that CRISPR/Cas9 is not yet ready for clinical use to correct mutations at this stage of human development, says the studys senior author Dieter Egli, assistant professor of developmental cell biology in the Department of Pediatrics at Columbia University Vagelos College of Physicians and Surgeons.

The genome editing system called CRISPR/Cas9 has revolutionized molecular biology in recent years, and its discoverers were honored with this year's Nobel Prize in chemistry. The system allows scientists to make precise changes in the genomes of cultured cells, living tissues, and animal embryos.

The first use of CRISPR in human embryos was reported in 2015. Then in 2018, He Jiankui claimed to have performed the procedure in a pair of twin embryos, eliciting a firestorm of condemnation from scientists and government officials worldwide.

In the new paper, Egli and his colleagues tested CRISPR/Cas9 genome editing's effects on early-stage human embryos carrying a mutation in a gene called EYS (eyes shut homolog), which causes hereditary blindness.

We know from previous studies in differentiated human cells and in mice that a break in the DNA results in mostly two outcomes: precise repair or small local changes. At the EYS gene, these changes can yield a functional gene, though it is not a perfect repair, says Michael Zuccaro, a research scientist at Columbia University Vagelos College of Physicians and Surgeons and co-lead author of the paper.

When Zuccaro, Egli, and their colleagues looked at the entire genomes of the modified embryos in this study, they identified another outcome. We learned that in human embryonic cells, a single break in the DNA can result in a third outcomethe loss of an entire chromosome or sometimes a large segment of that chromosome, and this loss of the chromosome is very frequent, says Zuccaro.

In 2017, a study reported the successful correction of a heart disease-causing mutation in normal human embryos using CRISPR. Comprehensive data from the new study offer a different interpretation of these results: Instead of being corrected, the chromosome carrying the mutation may have been lost altogether.

"If our results had been known two years ago, I doubt that anyone would have gone ahead with an attempt to use CRISPR to edit a gene in a human embryo in the clinic," Egli says.Our hope is that these cautionary findings should discourage premature clinical application of this important technologybut can also guide responsible research to achieve its ultimate safe and effective use.

Follow this link:
Study Identifies Pitfall for Correcting Mutations in Human Embryos with CRISPR - Columbia University Irving Medical Center

Monday, 2 November 2020, 10:20 amPress Release: Macular Degeneration New Zealand

49% of New Zealanders do not know anything aboutmacular degeneration which puts them at risk of missingkey signs in their own eye health

Thecondition is the most common cause of blindness but someforms are treatable if caught intime

Today marks the start of MacularDegeneration Awareness Week 2-9 November which aims toeducate New Zealanders about the simple steps they can taketo protect their vision

Its a conditionthat affects 1 in 7 New Zealanders aged 50+, rising to aquarter of those aged over 80, yet awareness of maculardegeneration is low, with almost half (49%) revealing theydo not know anything about the condition.

This is aproblem as early detection and treatment can reduceavoidable vision loss for the 1,500,000 New Zealanders atrisk.

The macula is the central part of the retina atthe back of the eye. The retina processes vision, andmacular degeneration causes progressive macula damage,leading to issues such as a loss of reading, recognisingfaces, and being able to drive. There are two types ofmacular degeneration, dry and wet. Dry macular degenerationresults in gradual loss of central vision. Wet maculardegeneration is characterised by a sudden loss of visioncaused by abnormal blood vessels growing under the retina.Immediate medical treatment of wet macular degeneration isessential for saving sight.

During awareness week acampaign by the charity to highlight what New Zealandersrisk losing if they dont take their eye health seriously,will feature on billboards across Auckland, Hamilton,Wellington and Christchurch. The posters show beautifulviews of New Zealand, obscured by a dark blur to show whatthe same vista might look like to someone suffering frommacular degeneration.

Phillippa Pitcher, GeneralManager at Macular Degeneration NZ says, Sadly maculardegeneration is not uncommon and the risks increase as weage. It is important that all New Zealanders aged 40+ gettheir eyes checked regularly but also crucially know thesigns to look out for so they can monitor their own eyehealth and get any abnormalities checked out quickly. Wehope that by raising awareness of the condition and thesigns to look out for we avoid future cases of needlessvision loss. Early detection and prompt treatment savessight.

Key signs to look out for when monitoringyour own eye health include;

Asimple test, available via the MDNZ website and youroptometrist, can lead to early diagnosis and treatment ofmacular degeneration, the most common cause ofblindness.

Visit http://www.mdnz.org.nz to findout more about macular degeneration including tips forstaying healthy and signs to look out for as well as eventstaking place during Macular Degeneration Awareness Week 2020 2-9 November.

Case studies are available onrequest.

Scoop Media

Become a member Find out more

Go here to read the rest:
Raising Awareness For Macular Degeneration, The Condition That Affects 1 In 7 Aged 50+ - Scoop.co.nz

By Christa Poggemiller| The Hawk Eye

Its hard to believe eight months have passed since we first starting hearing about COVID-19 and at least seven months since the first lockdowns.

Probably like a good majority of our neighbors, we have all grown tired of being cooped up, tired of having to worry about where you can safely go, or just plain worried about contracting COVID.

Over the past few months, I have written several articles to highlight what we can do to stay safe and prevent further COVID-19 community spread. I am not going to focus this article on COVID-19 anymore than to remind everyone, it is normal to have COVID fatigue and not feel motivated to follow the health strategies or even consider not following the recommendations when you are contacted by local health departments.

But the most important thing we can do for ourselves, our families and neighbors is to follow those isolation recommendations. Close contacts (those within six feet for a duration of 15-minutes) to a positive COVID case can become symptomatic and COVID positive literally at any time during their 14-day isolation. Once this person is positive, anyone they came in contact with during the 48-hours prior to having symptoms or a positive test will need to quarantine, and those people also could develop the virus, which means now they have exposed more families and people in the community.

Our current community 14-day rolling percentage has gone up significantly over the past few weeks. I am encouraging everyone to do their part to bring those numbers back down by following isolation recommendations and continuing to follow the guidelines: social distance, good handwashing and stay home when your sick.

Together, we will get through this.

During COVID-19, some of the other important health promotion activities or your routine health visits may gotten missed. Things like annual check-ups, childrens immunizations or flu shots may have gotten postponed and still havent been done. Now may be a good time to reach out to your health care provider or local health department and get those caught up. Maintaining good health, managing chronic diseases and early diagnosis is especially important to overall wellness.

Of those chronic diseases, diabetes is one that affected about 34.2 million Americans, or about 10.5% of the population, in 2018. According to American Diabetes Association, each year about 1.5 million Americans are diagnosed with diabetes, and another 7.3 million people go undiagnosed.

November is raising awareness about diabetes month. So, what is diabetes? Diabetes is a disease that affects how your body turns food into energy. If you have diabetes, your body either doesnt make enough insulin or cant use the insulin it makes as well as it should. When there isnt enough insulin or cells stop responding to insulin, too much blood sugar stays in your bloodstream, which can cause serious health problems over time.

Ninety-five percent of people with diabetes have Type 2. Common symptoms of Type 2 diabetes can include: excessive thirst, frequent urination, blurred vision, fatigue and unexpected weight loss. Its untreated Type 2 diabetes can lead to blindness, heart attack, kidney failure, stroke or loss of toes, feet or legs.

What can you do about it?

You dont have to make big changes to prevent or delay diabetes.

Before beginning any exercise or weight-loss program consult your healthcare provider. For more information visit: https://www.niddk.nih.gov/

Christa Poggemiller is director of Des Moines County Public Health.

Continue reading here:
In the Public Health: Don't let pandemic fatigue get the better of you - Burlington Hawk Eye

There are numerous eye-infections caused by various viruses, bacteria, parasites, and fungi that can invade the human body, and also have the potential of attacking the surface or interior of the eye. Eye infections can be the inflammation of the Conjunctiva (Conjunctivitis), eyelid (blepharitis), the cornea (keratitis), the liquid inside the eye (vitritis), the retina and the blood vessels that feed it (chorioretinitis), optic nerve (neuroretinitis) and others. The most commonly seen eye infection is conjunctivitis, caused by adenovirus, other cause of conjunctivitis is bacteria such as staphylococcus aureus which is common in children. Symptoms of eye infections may include redness, itching, swelling, photosentivity, tears, swollen eyelid & involuntary blinking discharge, pain, or problems with vision. Whereas many eye infections have potential to cause significant damage to retina, formation of scars and ulcers in the cornea ultimately damaging the vision of an individual temporarily or permanently. Treatment depends on the cause of the infection and may include compresses, eye drops, creams, or oral antibiotics therapy. Eye infections treatment market includes the medicines used in treating eye infections. Eye infection can be treated by analyzing the cause of infecting agent and treating the cause as per required. For example bacterial infections are treated through antibiotics eye drop or ointments. Fungal infection as against is resolved on their own or by prescribing anti-fungal eye drops.

Request Sample Copy Of this Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1300

Eye Infections Treatment Market: Drivers & Restraints

Eye infections treatment market is growing, this is attributed to aging population, rising prevalence of ophthalmic diseases, increasing company investments for launching new product forms, health conscious population, free eye check-up camps funded by the government in the different regions. Secondly rising awareness regarding various eye infections and rising prevalence of blindness amongst the geriatric population driving the growth of eye infection treatment market. However stringent government regulations in various drugs development procedures and the side effects associated with various antibiotics would impede the adoption of eye infection pharmaceutical treatment, thereby, hamper the market growth.

Eye Infections Treatment Market: Segmentation

This market is segmented on the basis of product type, distribution channel and drug class

Segmentation based on product type

Segmentation based on distribution channel

Visit For [emailprotected] https://www.futuremarketinsights.com/toc/rep-gb-1300

Eye Infections Treatment Market: Overview

There are different OTC as well as prescription based drugs available in the market to treat eye infection including artificial tear drops, ointments, eye wash, hyper osmotic, scrub, decongestants, and antihistamines, antibacterial, antifungal, and antiviral. Some of the important and widely used drugs in ocular infections include Fluoroquinolones, Aminoglycosides, Macrolides and Others.

Eye Infections TreatmentMarket: Region-wise Outlook

Globally, the eye infections treatment market is expected to witness healthy growth in the near future due to increasing awareness about eye care, global aging population and the rise in per capita expenditure on healthcare in the developing nations. North America region dominate the eye infection treatment followed by Europe owing to technological advancement and more number of market players in these regions. Asia-Pacific market is expected to register fastest growth owing to the rise in geriatric population and also the rise in prevalence of blindness in geriatric population.

Eye Infections Treatment Market: Key Players

Some of the key market players in global Point of care test market are Allergan Inc., Alcon Laboratories Inc., Johnson & Johnson Ltd., Pfizer Inc., Merck & Co., Inc., Novartis, Santen Pharmaceuticals, Valeant Pharmaceuticals Inc., Bayer, GlaxoSmithKline, Sanofi-Aventis and Bausch & Lomb, Inc.,

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.

The report covers exhaustive analysis on:

Regional analysis includes

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Originally posted here:
Sales of Eye Infections Treatment to Decelerate in 2020 as COVID-19 Pandemic Takes its Toll on Global Market - PRnews Leader

The Exosome Therapeutic Market study consists of a market attractiveness analysis, wherein each segment is benchmarked based on its market size, growth rate, and general attractiveness. The report is based on the market type, organization size, availability on-premises and the end-users organization type, and the availability in areas such as North America, South America, Europe, Asia-Pacific & Middle East & Africa. The info covered helps businesses know how patents, licensing agreements and other legal restrictions affect the manufacture and sale of the firms products. An influential Exosome Therapeutic Market report reveals the nature of demand for the firms product to know if the demand for the product is constant or seasonal.

Get Sample PDF (including COVID19 Impact Analysis) of Market Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-exosome-therapeutic-market&rp

Market Analysis and Insights:Global Exosome Therapeutic Market

Exosome therapeutic market is expected to gain market growth in the forecast period of 2019 to 2026. Data Bridge Market Research analyses that the market is growing with a CAGR of 21.9% in the forecast period of 2019 to 2026 and expected to reach USD 31,691.52 million by 2026 from USD 6,500.00 million in 2018. Increasing prevalence of lyme disease, chronic inflammation, autoimmune disease and other chronic degenerative diseases are the factors for the market growth.

The major players covered in theExosome Therapeutic Marketreport areevox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United Therapeutics Corporation, Codiak BioSciences, Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, ReNeuron Group plc, Capricor Therapeutics, Avalon Globocare Corp., CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC., Stem Cells Group among other players domestic and global.Exosome therapeutic market share data is available for Global, North America, Europe, Asia-Pacific, and Latin America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Get Full TOC, Tables and Figures of Market Report @https://www.databridgemarketresearch.com/toc/?dbmr=global-exosome-therapeutic-market&rp

Exosomes are used to transfer RNA, DNA, and proteins to other cells in the body by making alteration in the function of the target cells. Increasing research activities in exosome therapeutic is augmenting the market growth as demand for exosome therapeutic has increased among healthcare professionals.

Increased number of exosome therapeutics as compared to the past few years will accelerate the market growth. Companies are receiving funding for exosome therapeutic research and clinical trials. For instance, In September 2018, EXOCOBIO has raised USD 27 million in its series B funding. The company has raised USD 46 million as series a funding in April 2017. The series B funding will help the company to set up GMP-compliant exosome industrial facilities to enhance production of exosomes to commercialize in cosmetics and pharmaceutical industry.

Increasing demand for anti-aging therapies will also drive the market. Unmet medical needs such as very few therapeutic are approved by the regulatory authority for the treatment in comparison to the demand in global exosome therapeutics market will hamper the market growth market. Availability of various exosome isolation and purification techniques is further creates new opportunities for exosome therapeutics as they will help company in isolation and purification of exosomes from dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, and urine and from others sources. Such policies support exosome therapeutic market growth in the forecast period to 2019-2026.

This exosome therapeutic market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for anAnalyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Exosome Therapeutic Market Scope and Market Size

Global exosome therapeutic market is segmented of the basis of type, source, therapy, transporting capacity, application, route of administration and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Based on type, the market is segmented into natural exosomes and hybrid exosomes. Natural exosomes are dominating in the market because natural exosomes are used in various biological and pathological processes as well as natural exosomes has many advantages such as good biocompatibility and reduced clearance rate compare than hybrid exosomes.

Exosome is an extracellular vesicle which is released from cells, particularly from stem cells. Exosome functions as vehicle for particular proteins and genetic information and other cells. Exosome plays a vital role in the rejuvenation and communication of all the cells in our body while not themselves being cells at all. Research has projected that communication between cells is significant in maintenance of healthy cellular terrain. Chronic disease, age, genetic disorders and environmental factors can affect stem cells communication with other cells and can lead to distribution in the healing process. The growth of the global exosome therapeutic market reflects global and country-wide increase in prevalence of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases, along with increasing demand for anti-aging therapies. Additionally major factors expected to contribute in growth of the global exosome therapeutic market in future are emerging therapeutic value of exosome, availability of various exosome isolation and purification techniques, technological advancements in exosome and rising healthcare infrastructure.

Rising demand of exosome therapeutic across the globe as exosome therapeutic is expected to be one of the most prominent therapies for autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases treatment, according to clinical researches exosomes help to processes regulation within the body during treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases. This factor has increased the research activities in exosome therapeutic development around the world for exosome therapeutic. Hence, this factor is leading the clinician and researches to shift towards exosome therapeutic. In the current scenario the exosome therapeutic are highly used in treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases and as anti-aging therapy as it Exosomes has proliferation of fibroblast cells which is significant in maintenance of skin elasticity and strength.

Based on source, the market is segmented into dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, urine and others. Mesenchymal stem cells are dominating in the market because mesenchymal stem cells (MSCs) are self-renewable, multipotent, easily manageable and customarily stretchy in vitro with exceptional genomic stability. Mesenchymal stem cells have a high capacity for genetic manipulation in vitro and also have good potential to produce. It is widely used in treatment of inflammatory and degenerative disease offspring cells encompassing the transgene after transplantation.

Based on therapy, the market is segmented into immunotherapy, gene therapy and chemotherapy. Chemotherapy is dominating in the market because chemotherapy is basically used in treatment of cancer which is major public health issues. The multidrug resistance (MDR) proteins and various tumors associated exosomes such as miRNA and IncRNA are include in in chemotherapy associated resistance.

Based on transporting capacity, the market is segmented into bio macromolecules and small molecules. Bio macromolecules are dominating in the market because bio macromolecules transmit particular biomolecular information and are basically investigated for their delicate properties such as biomarker source and delivery system.

Based on application, the market is segmented into oncology, neurology, metabolic disorders, cardiac disorders, blood disorders, inflammatory disorders, gynecology disorders, organ transplantation and others. Oncology segment is dominating in the market due to rising incidence of various cancers such as lung cancer, breast cancer, leukemia, skin cancer, lymphoma. As per the National Cancer Institute, in 2018 around 1,735,350 new cases of cancer was diagnosed in the U.S. As per the American Cancer Society Inc in 2019 approximately 268,600 new cases of breast cancer diagnosed in the U.S.

Based on route of administration, the market is segmented into oral and parenteral. Parenteral route is dominating in the market because it provides low drug concentration, free from first fast metabolism, low toxicity as compared to oral route as well as it is suitable in unconscious patients, complicated to swallow drug etc.

The exosome therapeutic market, by end user, is segmented into hospitals, diagnostic centers and research & academic institutes. Hospitals are dominating in the market because hospitals provide better treatment facilities and skilled staff as well as treatment available at affordable cost in government hospitals.

Exosome therapeutic Market Country Level Analysis

The global exosome therapeutic market is analysed and market size information is provided by country by type, source, therapy, transporting capacity, application, route of administration and end user as referenced above.

The countries covered in the exosome therapeutic market report are U.S. and Mexico in North America, Turkey in Europe, South Korea, Australia, Hong Kong in the Asia-Pacific, Argentina, Colombia, Peru, Chile, Ecuador, Venezuela, Panama, Dominican Republic, El Salvador, Paraguay, Costa Rica, Puerto Rico, Nicaragua, Uruguay as part of Latin America.

Country Level Analysis, By Type

North America dominates the exosome therapeutic market as the U.S. is leader in exosome therapeutic manufacturing as well as research activities required for exosome therapeutics. At present time Stem Cells Group holding shares around 60.00%. In addition global exosomes therapeutics manufacturers like EXOCOBIO, evox THERAPEUTICS and others are intensifying their efforts in China. The Europe region is expected to grow with the highest growth rate in the forecast period of 2019 to 2026 because of increasing research activities in exosome therapeutic by population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Huge Investment by Automakers for Exosome Therapeutics and New Technology Penetration

Global exosome therapeutic market also provides you with detailed market analysis for every country growth in pharma industry with exosome therapeutic sales, impact of technological development in exosome therapeutic and changes in regulatory scenarios with their support for the exosome therapeutic market. The data is available for historic period 2010 to 2017.

Competitive Landscape and Exosome Therapeutic Market Share Analysis

Global exosome therapeutic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, concept cars, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companys focus related to global exosome therapeutic market.

Many joint ventures and developments are also initiated by the companies worldwide which are also accelerating the global exosome therapeutic market.

For instance,

Partnership, joint ventures and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for exosome therapeutics through expanded model range.

Customization Available:Global Exosome Therapeutic Market

Data Bridge Market Researchis a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-exosome-therapeutic-market&rp

About Data Bridge Market Research :

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us :

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Mail:Corporatesales@databridgemarketresearch.com

Read more here:
Exosome Therapeutic Market is Booming With Healthy CAGR || Major Gaints Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, ReNeuron...

This Exosome Therapeutic Market research report is a great store to acquire current as well as upcoming technical and financial details of the industry for the precise forecast period. This market report also provides information about the brand awareness, market landscape, possible future issues, industry trends and customer behaviour for the industry. It also assesses the market status, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, distributors & Porters Five Forces Analysis. It saves precious time as well as puts in credibility to the work that is performed to grow business.

Exosome Therapeutic Market report is an important source of guidance for companies and individuals offering industry chain structure, business strategies and proposals for new project investments. This Exosome Therapeutic Market report has a chapter on the Global Exosome Therapeutic Market and all its associated companies with their profiles, which provides valuable data related to their outlook in terms of finances, product portfolios, investment plans, and marketing and business strategies. The Exosome Therapeutic Market report is worked upon with the best-practice models, comprehensive market analysis and research methodologies so that clients achieve perfect market segmentation and insights.

Get Sample PDF (including COVID19 Impact Analysis) of Market Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-exosome-therapeutic-market&rp

Market Analysis and Insights:Global Exosome Therapeutic Market

Exosome therapeutic market is expected to gain market growth in the forecast period of 2019 to 2026. Data Bridge Market Research analyses that the market is growing with a CAGR of 21.9% in the forecast period of 2019 to 2026 and expected to reach USD 31,691.52 million by 2026 from USD 6,500.00 million in 2018. Increasing prevalence of lyme disease, chronic inflammation, autoimmune disease and other chronic degenerative diseases are the factors for the market growth.

The major players covered in theExosome Therapeutic Marketreport areevox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United Therapeutics Corporation, Codiak BioSciences, Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, ReNeuron Group plc, Capricor Therapeutics, Avalon Globocare Corp., CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC., Stem Cells Group among other players domestic and global.Exosome therapeutic market share data is available for Global, North America, Europe, Asia-Pacific, and Latin America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Get Full TOC, Tables and Figures of Market Report @https://www.databridgemarketresearch.com/toc/?dbmr=global-exosome-therapeutic-market&rp

Exosomes are used to transfer RNA, DNA, and proteins to other cells in the body by making alteration in the function of the target cells. Increasing research activities in exosome therapeutic is augmenting the market growth as demand for exosome therapeutic has increased among healthcare professionals.

Increased number of exosome therapeutics as compared to the past few years will accelerate the market growth. Companies are receiving funding for exosome therapeutic research and clinical trials. For instance, In September 2018, EXOCOBIO has raised USD 27 million in its series B funding. The company has raised USD 46 million as series a funding in April 2017. The series B funding will help the company to set up GMP-compliant exosome industrial facilities to enhance production of exosomes to commercialize in cosmetics and pharmaceutical industry.

Increasing demand for anti-aging therapies will also drive the market. Unmet medical needs such as very few therapeutic are approved by the regulatory authority for the treatment in comparison to the demand in global exosome therapeutics market will hamper the market growth market. Availability of various exosome isolation and purification techniques is further creates new opportunities for exosome therapeutics as they will help company in isolation and purification of exosomes from dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, and urine and from others sources. Such policies support exosome therapeutic market growth in the forecast period to 2019-2026.

This exosome therapeutic market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for anAnalyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Exosome Therapeutic Market Scope and Market Size

Global exosome therapeutic market is segmented of the basis of type, source, therapy, transporting capacity, application, route of administration and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Based on type, the market is segmented into natural exosomes and hybrid exosomes. Natural exosomes are dominating in the market because natural exosomes are used in various biological and pathological processes as well as natural exosomes has many advantages such as good biocompatibility and reduced clearance rate compare than hybrid exosomes.

Exosome is an extracellular vesicle which is released from cells, particularly from stem cells. Exosome functions as vehicle for particular proteins and genetic information and other cells. Exosome plays a vital role in the rejuvenation and communication of all the cells in our body while not themselves being cells at all. Research has projected that communication between cells is significant in maintenance of healthy cellular terrain. Chronic disease, age, genetic disorders and environmental factors can affect stem cells communication with other cells and can lead to distribution in the healing process. The growth of the global exosome therapeutic market reflects global and country-wide increase in prevalence of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases, along with increasing demand for anti-aging therapies. Additionally major factors expected to contribute in growth of the global exosome therapeutic market in future are emerging therapeutic value of exosome, availability of various exosome isolation and purification techniques, technological advancements in exosome and rising healthcare infrastructure.

Rising demand of exosome therapeutic across the globe as exosome therapeutic is expected to be one of the most prominent therapies for autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases treatment, according to clinical researches exosomes help to processes regulation within the body during treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases. This factor has increased the research activities in exosome therapeutic development around the world for exosome therapeutic. Hence, this factor is leading the clinician and researches to shift towards exosome therapeutic. In the current scenario the exosome therapeutic are highly used in treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases and as anti-aging therapy as it Exosomes has proliferation of fibroblast cells which is significant in maintenance of skin elasticity and strength.

Based on source, the market is segmented into dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, urine and others. Mesenchymal stem cells are dominating in the market because mesenchymal stem cells (MSCs) are self-renewable, multipotent, easily manageable and customarily stretchy in vitro with exceptional genomic stability. Mesenchymal stem cells have a high capacity for genetic manipulation in vitro and also have good potential to produce. It is widely used in treatment of inflammatory and degenerative disease offspring cells encompassing the transgene after transplantation.

Based on therapy, the market is segmented into immunotherapy, gene therapy and chemotherapy. Chemotherapy is dominating in the market because chemotherapy is basically used in treatment of cancer which is major public health issues. The multidrug resistance (MDR) proteins and various tumors associated exosomes such as miRNA and IncRNA are include in in chemotherapy associated resistance.

Based on transporting capacity, the market is segmented into bio macromolecules and small molecules. Bio macromolecules are dominating in the market because bio macromolecules transmit particular biomolecular information and are basically investigated for their delicate properties such as biomarker source and delivery system.

Based on application, the market is segmented into oncology, neurology, metabolic disorders, cardiac disorders, blood disorders, inflammatory disorders, gynecology disorders, organ transplantation and others. Oncology segment is dominating in the market due to rising incidence of various cancers such as lung cancer, breast cancer, leukemia, skin cancer, lymphoma. As per the National Cancer Institute, in 2018 around 1,735,350 new cases of cancer was diagnosed in the U.S. As per the American Cancer Society Inc in 2019 approximately 268,600 new cases of breast cancer diagnosed in the U.S.

Based on route of administration, the market is segmented into oral and parenteral. Parenteral route is dominating in the market because it provides low drug concentration, free from first fast metabolism, low toxicity as compared to oral route as well as it is suitable in unconscious patients, complicated to swallow drug etc.

The exosome therapeutic market, by end user, is segmented into hospitals, diagnostic centers and research & academic institutes. Hospitals are dominating in the market because hospitals provide better treatment facilities and skilled staff as well as treatment available at affordable cost in government hospitals.

Exosome therapeutic Market Country Level Analysis

The global exosome therapeutic market is analysed and market size information is provided by country by type, source, therapy, transporting capacity, application, route of administration and end user as referenced above.

The countries covered in the exosome therapeutic market report are U.S. and Mexico in North America, Turkey in Europe, South Korea, Australia, Hong Kong in the Asia-Pacific, Argentina, Colombia, Peru, Chile, Ecuador, Venezuela, Panama, Dominican Republic, El Salvador, Paraguay, Costa Rica, Puerto Rico, Nicaragua, Uruguay as part of Latin America.

Country Level Analysis, By Type

North America dominates the exosome therapeutic market as the U.S. is leader in exosome therapeutic manufacturing as well as research activities required for exosome therapeutics. At present time Stem Cells Group holding shares around 60.00%. In addition global exosomes therapeutics manufacturers like EXOCOBIO, evox THERAPEUTICS and others are intensifying their efforts in China. The Europe region is expected to grow with the highest growth rate in the forecast period of 2019 to 2026 because of increasing research activities in exosome therapeutic by population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Huge Investment by Automakers for Exosome Therapeutics and New Technology Penetration

Global exosome therapeutic market also provides you with detailed market analysis for every country growth in pharma industry with exosome therapeutic sales, impact of technological development in exosome therapeutic and changes in regulatory scenarios with their support for the exosome therapeutic market. The data is available for historic period 2010 to 2017.

Competitive Landscape and Exosome Therapeutic Market Share Analysis

Global exosome therapeutic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, concept cars, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companys focus related to global exosome therapeutic market.

Many joint ventures and developments are also initiated by the companies worldwide which are also accelerating the global exosome therapeutic market.

For instance,

Partnership, joint ventures and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for exosome therapeutics through expanded model range.

Customization Available:Global Exosome Therapeutic Market

Data Bridge Market Researchis a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-exosome-therapeutic-market&rp

About Data Bridge Market Research :

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us :

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Mail:[emailprotected]

Excerpt from:
Exosome Therapeutic Market 2020-2026 Executive Summary, Introduction, Sizing, Analysis and Forecast || Major Gaints Jazz Pharmaceuticals, Inc.,...

The potential of gene therapies as cures for some hard-to-treat genetic diseases can be very attractive. But one such product is now suspected of causing a serious safety problem.

Friday, Orchard Therapeutics said its Strimvelis treatment, approved by European authorities in 2016 to treatthe rare inherited condition ADA-SCID, has been linked to a patients leukemia.

Preliminary findings suggest this diagnosis may be attributable to an insertional event related to treatment with Strimvelis, the company said. Its now investigating whether theres indeed a causal relationship.

How technologies are transforming high volume injections - essential enablers for patient outcomes

Therapies requiring high volume injections are becoming more common across a broad range of therapeutic areas. This webinar will explore why adherence, safety and quality of life are important for patients, and how these key enablers contribute towards positive outcomes. We will also discuss existing challenges, such as drug development, regulatory, patient accessibility, and how device technologies can further improve patient outcomes. Register Today!

Since its 2016 EU approvalwhen it was owned by original developer GlaxoSmithKlineonly 16 patients have been treated with Stimvelis. The patient who developed leukemia had apparently been treated under a GSK compassionate use program in 2016.

No more patients will get the therapy before the investigation is complete, Orchard said. The drug was never approved in the U.S.

ADA-SCIDis a condition marked by a mutation in the gene making the adenosine deaminase (ADA) enzyme, which is essential for maintaining normal white blood cells. ADA-SCID patients, with a dysfunctional immune system, have less than two years to live without effective intervention.

RELATED:Orchard licenses gene therapy tech from GSK

Strimvelis, originally developed by GSK and bought by Orchard in 2018, offers an option for patients who cant find a matched stem cell donor. It works by editing the patients own hematopoietic stem cells with the functional ADA gene. The cells arethen transferred back into the patient's bone marrow to mature and produce the normal ADA protein.

The therapy uses a gammaretrovirus as the vector to carry the gene. Problem is, retrovirus can incorporate their own genetic information into the human genome, causing unintended changes that can give rise to cancer. It is a known risk factor of gammaretroviral vector-based gene therapy and has been described as one of the important potential risks for Strimvelis in its EU approval.

Besides Strimvelis, Orchard is also developing OTL-101, which uses a lentivirus to insert a functional copy of the ADA gene into a patients cells. The drug is currently undergoing a registrational trial and has won breakthrough and orphan drug designations from the FDA.

All the gene therapy candidates in Orchards pipeline use lentiviral vectors that have been specifically designed to avoid insertional oncogenesis after administration, Orchard said, adding that no dangerous gene insertion has been reported around lentiviral vector-based stem cell gene therapy in any indication.

Read more:
Orchard Therapeutics' gene therapy Strimvelis linked to a leukemia case - FiercePharma

In a normal eye, opsins are expressed by the rod and cone photoreceptors in the retina. When activated by light, the photoreceptors pulse and send a signal through other retinal neurons, the optic nerve, and on to neurons in the brain.

A variety of common eye diseases, including age-related macular degeneration and retinitis pigmentosa, damage the photoreceptors, impairing vision. But while the photoreceptors may no longer fully function, other retinal neurons (bipolar cells) remain intact. The team identified a way for bipolar cells to take on some of the work of damaged photoreceptors.

The beauty of our strategy is its simplicity, said Samarendra Mohanty, PhD, Nanoscope founder and corresponding author of a report on the mouse study that appears today in Nature Gene Therapy. Bipolar cells are downstream from the photoreceptors, so when the MCO1 opsin gene is added to bipolar cells in a retina with nonfunctioning photoreceptors, light sensitivity is restored.

The strategy could overcome challenges plagued by other approaches to retinal regeneration, according to the researchers. Gene replacement therapy has thus far worked principally in rare diseases that leave photoreceptors intact.

Under a best-case scenario, the therapy could help patients achieve 20/60 vision, according to the researchers; however, no one knows how the restored vision will compare to normal vision.

Read the original post

Read the original post:
Gene therapy may be able to restore vision - Genetic Literacy Project

Avantor executives joined other industry leaders at virtual Cell & Gene Therapy Bioprocessing & Commercialization Conference

Panels discussed critical topics including process efficiency and scaling solutions

RADNOR, Pa., Nov. 2, 2020 /PRNewswire/ --Executives from Avantor Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, recently provided expert insight at the Cell & Gene Therapy Bioprocessing & Commercialization Virtual Conference. Cell and gene therapy (C>) are two of the most revolutionary applications driving the biopharmaceutical industry.

In separate panel discussions with other global industry leaders, Dr. Ger Brophy, EVP, Biopharma Production at Avantor and Claudia Berrn, SVP, Business Development and Commercial Operations at Avantor, each addressed novel considerations and challenges facing the biopharmaceutical industry, including the impact of COVID-19. They highlighted innovation to help drive the creation and commercialization of life-changing, personalized C> treatments.

In a panel on the evolution of C> and the path toward scalability and manufacturability of these treatments, Dr. Brophy gave his perspective on this growing need for the bioprocessing industry.

"Genuine progress is being made in the long-standing battle to effectively treat and control disease, and cell & gene therapies will only continue to unlock new frontiers in medicine," said Dr. Brophy. "We're beginning to see more clearly the issues that need to be addressed, and know that if products are to scale and become more accessible to patients worldwide, there needs to be efficiency in operations. There is an absolute requirement for automation, both to reduce variability and to generate process efficiencies. At Avantor, we are ready to make the essential materials and technologies available to companies leading the charge and treating patients. Innovation and agility are central to how we're partnering with the industry to resolve these issues."

On a separate panel, Ms. Berrn highlighted how the industry is navigating the challenges and impact of the global pandemic, from the fragmentation of supply chains to clinical trial disruption.

"In this critical moment for the industry and the world, it is more important than ever for leaders in the cell & gene therapy community to come together to strategize and share ideas," said Ms. Berrn. "Avantor is actively working with the world's leading pharmaceutical and biotechnology companies to accelerate the production of novel treatments. Collectively, our goal is to mitigate any challenges in the process of taking a groundbreaking treatment from its initial scientific discovery to delivery in treating patients."

Avantor provides products for biopharma production workflows, including cell and gene therapy offering. Search 'Avantor biopharma' in your browser.

About AvantorAvantor, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. One of our greatest strengths comes from having a global infrastructure that is strategically located to support the needs of our customers. Our global footprint enables us to serve more than 225,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries.We set science in motion to create a better world. For information, visit avantorsciences.com and find us on LinkedIn, Twitter and Facebook.

Robert DonohoeSenior Director, Corporate CommunicationsAvantorM: 484-688-4730[emailprotected]

Source: Avantor and Financial News

SOURCE Avantor and Financial News

http://avantorsciences.com

The rest is here:
Avantor Discusses Cell & Gene Therapy Production Trends Through the Lens of COVID-19 - PRNewswire